Data presented at the American Society of Hematology (ASH) Annual Meeting and Exposition showed the benefits of using Arganine (Arg) to supplement treatment of vaso-occlusive episdes (VOEs) in patients with sickle cell disease (SCD).
While statistically insignificant, they observed a clinically relevant decrease in total parenteral opioid (TPO) and a shortened time to crisis resolution in both intervention groups treated with Arg compared with placebo. Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
read more